Clinical trials: With/Without Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
The purpose of this study is to evaluate the glycemic control and safety of SHR-3167 and Insulin Degludec in type 2 diabetic participants treated with basal insulin with or without oral antidiabetic drugs.
- Trial name
- NCT07018453
- Testing
- SHR-3167, Insulin Degludec
- Where
- 2 sites in China
- Volunteers
- 173 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
Safety and Performance of the Glyconics-SX System (ANODE02)
The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or…
- Trial name
- ANODE02 (NCT05476016)
- Testing
- Near-infrared (NIR)
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Glyconics Ltd
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590797
- Testing
- Sitagliptin, Insulin, Metformin
- Volunteers
- 467 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- AZD6234
- Where
- 212 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Obesity, Type 2 Diabetes Mellitus (T2DM)
MagDI Italian Study
The objective of the MagDI Italy Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Conditions
- Obesity, Type 2 Diabetes Mellitus (T2DM), Anastomosis
- Trial name
- NCT06613711
- Testing
- Magnet System, DI Biofragmentable
- Where
- 4 sites in Italy
- Volunteers
- 27 people
- Sponsor
- GT Metabolic Solutions, Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral…
- Trial name
- NCT00791895
- Testing
- biphasic insulin aspart 30
- Where
- 15 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in…
- Trial name
- NCT07099742
- Testing
- Tirzepatide, Life Style Modification
- Where
- 3 sites in Bangladesh
- Volunteers
- 364 people
- Sponsor
- Dr. Md. Alimur Reza
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of LY2189102 in Patients With Type 2 Diabetes
Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes.
- Trial name
- NCT00942188
- Testing
- LY2189102
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a…
- Trial name
- NCT06297603
- Testing
- Retatrutide
- Where
- 76 sites in United States, Argentina and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 2 (NCT04770532)
- Testing
- Insulin degludec, Insulin Icodec
- Where
- 88 sites in United States, Bulgaria and 7 more
- Volunteers
- 526 people
- Sponsor
- Novo Nordisk A/S
Weight Management
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and…
- Trial name
- Embold (NCT07667803)
- Testing
- Elecoglipron
- Where
- 325 sites in United States, Argentina and 17 more
- Volunteers
- 4,500 people
- Sponsor
- AstraZeneca
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Obesity
Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System
This is an operationally seamless, open-label, multicenter study enrolling up to 50 subjects with obesity and with or without type 2 diabetes at up to 5 study centers across Canada and Europe who will undergo sleeve gastrectomy…
- Trial name
- NCT05322122
- Testing
- Side-to-side anastomosis duodeno-ileostomy diversion procedure
- Where
- 4 sites in Belgium, Canada and 2 more
- Volunteers
- 49 people
- Sponsor
- GT Metabolic Solutions, Inc.
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Renal Impairment
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
- Conditions
- Diabetes Mellitus, Type 2, Renal Impairment, Healthy
- Trial name
- NCT04616027
- Testing
- PF-06882961 20 mg
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S